GEAP202516637A - Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain - Google Patents
Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of painInfo
- Publication number
- GEAP202516637A GEAP202516637A GEAP202516637A GEAP2025016637A GEAP202516637A GE AP202516637 A GEAP202516637 A GE AP202516637A GE AP202516637 A GEAP202516637 A GE AP202516637A GE AP2025016637 A GEAP2025016637 A GE AP2025016637A GE AP202516637 A GEAP202516637 A GE AP202516637A
- Authority
- GE
- Georgia
- Prior art keywords
- pain
- treatment
- compounds
- bicyclic heterocyclic
- heterocyclic amide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202211024240 | 2022-04-25 | ||
| IN202311013223 | 2023-02-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GEAP202516637A true GEAP202516637A (en) | 2025-03-25 |
Family
ID=86469337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP202516637A GEAP202516637A (en) | 2022-04-25 | 2023-04-25 | Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP4514789A1 (enExample) |
| JP (1) | JP2025516005A (enExample) |
| KR (1) | KR20250006217A (enExample) |
| CN (1) | CN119585247A (enExample) |
| AU (1) | AU2023263309A1 (enExample) |
| CA (1) | CA3256486A1 (enExample) |
| CL (1) | CL2024003258A1 (enExample) |
| CO (1) | CO2024015763A2 (enExample) |
| CR (1) | CR20240512A (enExample) |
| DO (1) | DOP2024000215A (enExample) |
| GE (1) | GEAP202516637A (enExample) |
| IL (1) | IL316433A (enExample) |
| JO (1) | JOP20240238A1 (enExample) |
| MX (1) | MX2024013065A (enExample) |
| PE (1) | PE20251183A1 (enExample) |
| WO (1) | WO2023211990A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4570788A1 (en) | 2022-08-12 | 2025-06-18 | Guangzhou Fermion Technology Co., Ltd. | Compound as voltage-gated sodium channel inhibitor |
| US20250186419A1 (en) | 2023-12-07 | 2025-06-12 | Vertex Pharmaceuticals Incorporated | Dosing regimens for treating pain |
| WO2025228420A1 (zh) * | 2024-04-30 | 2025-11-06 | 江苏恒瑞医药股份有限公司 | 芳香环类化合物、其制备方法及其在医药上的应用 |
| WO2026001999A1 (zh) * | 2024-06-25 | 2026-01-02 | 江苏恒瑞医药股份有限公司 | 芳香环类化合物、其制备方法及其在医药上的应用 |
| CN121378214A (zh) * | 2024-07-23 | 2026-01-23 | 成都康弘药业集团股份有限公司 | 一种合成Nav1.8抑制剂的中间体，其制备方法和用途 |
| WO2026030525A1 (en) | 2024-07-31 | 2026-02-05 | Vertex Pharmaceuticals Incorporated | Zilvetrigine dosage forms and dosing regimens for treating pain |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| DE3211934A1 (de) * | 1982-03-31 | 1983-10-13 | Hoechst Ag, 6230 Frankfurt | Salicylsaeurederivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
| KR890002631B1 (ko) | 1984-10-04 | 1989-07-21 | 몬산토 캄파니 | 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물 |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| WO1997001331A2 (en) | 1995-06-27 | 1997-01-16 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| ES2221019T3 (es) | 1996-10-31 | 2004-12-16 | Takeda Chemical Industries, Ltd. | Preparacion de liberacion mantenida. |
| ZA9711385B (en) | 1996-12-20 | 1999-06-18 | Takeda Chemical Industries Ltd | Method of producing a sustained-release preparation |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| JP2006503094A (ja) * | 2002-10-16 | 2006-01-26 | スミスクライン ビーチャム コーポレーション | 化合物 |
| ATE540033T1 (de) * | 2005-11-14 | 2012-01-15 | Vertex Pharma | Als modulatoren von spannungsgesteuerten ionenkanälen geeignete chinazoline |
| WO2008135830A1 (en) | 2007-05-03 | 2008-11-13 | Pfizer Limited | N- [6-amino-s- (phenyl) pyrazin-2-yl] -isoxazole-4-carboxamide derivatives and related compounds as nav1.8 channel modulators for the treatment of pain |
| MD20140037A2 (ro) | 2011-10-26 | 2014-08-31 | Pfizer Limited | Derivaţi de (4-fenilimidazol-2-il)etilamină utili ca modulatori ai canalului de sodiu |
| CA2861439C (en) | 2012-02-03 | 2016-07-12 | Pfizer Inc. | Benzimidazole and imidazopyridine derivatives as sodium channel modulators |
| AR094668A1 (es) | 2013-01-31 | 2015-08-19 | Vertex Pharma | Amidas como moduladores de canales de sodio |
| ES2857687T3 (es) | 2013-01-31 | 2021-09-29 | Vertex Pharma | Piridona amidas como moduladores de los canales de sodio |
| CN105073738B (zh) | 2013-01-31 | 2018-01-05 | 沃泰克斯药物股份有限公司 | 作为钠通道调节剂的喹啉及喹喔啉酰胺类 |
| PE20160548A1 (es) | 2013-07-19 | 2016-05-21 | Vertex Pharma | Sulfonamidas como moduladores de canales de sodio |
| CA2931550C (en) | 2013-12-13 | 2023-09-26 | Vertex Pharmaceuticals Incorporated | Prodrugs of pyridone amides useful as modulators of sodium channels |
| RS60906B1 (sr) * | 2014-10-06 | 2020-11-30 | Vertex Pharma | Modulatori regulatora transmembranske provodljivosti za cističnu fibrozu |
| EP3625214B1 (en) | 2017-05-16 | 2022-07-06 | Vertex Pharmaceuticals Incorporated | Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels |
| CA3069720A1 (en) | 2017-07-11 | 2019-01-17 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| WO2019157505A1 (en) | 2018-02-12 | 2019-08-15 | Vertex Pharmaceuticals Incorporated | A method of treating pain |
| AU2019301628C1 (en) | 2018-07-09 | 2025-02-06 | Lieber Institute, Inc. | Pyridine carboxamide compounds for inhibiting NaV1.8 |
| SG11202100137TA (en) | 2018-07-09 | 2021-02-25 | Lieber Institute Inc | PYRIDAZINE COMPOUNDS FOR INHIBITING Nav1.8 |
| KR102860523B1 (ko) | 2018-11-02 | 2025-09-16 | 머크 샤프 앤드 돔 엘엘씨 | Nav1.8 억제제로서의 2-아미노-n-헤테로아릴-니코틴아미드 |
| US12344595B2 (en) | 2018-11-02 | 2025-07-01 | Merck Sharp & Dohme Llc | 2-amino-n-phenyl-nicotinamides as NAV1.8 inhibitors |
| WO2020146682A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| WO2020219867A1 (en) | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Pyridone amide co-crystal compositions for the treatment of pain |
| US20230103791A1 (en) | 2019-06-27 | 2023-04-06 | Glaxosmithkline Intellectual Property Development Limited | 2,3-dihydroquinazolin compounds as nav1.8 inhibitors |
| WO2021032074A1 (zh) | 2019-08-19 | 2021-02-25 | 江苏恒瑞医药股份有限公司 | 苯甲酰胺稠芳环类衍生物、其制备方法及其在医药上的应用 |
| MX2022006865A (es) | 2019-12-06 | 2022-07-11 | Vertex Pharma | Tetrahidrofuranos sustituidos como moduladores de canales de sodio. |
| BR112022024476A2 (pt) | 2020-06-17 | 2022-12-27 | Merck Sharp & Dohme Llc | 5-oxopirrolidino-3-carboxamidas como inibidores de nav1.8 |
| EP4167994A4 (en) | 2020-06-17 | 2024-07-24 | Merck Sharp & Dohme LLC | 2-OXO-OXAZOLIDINE-5-CARBOXAMIDE AS NAV1.8 INHIBITORS |
| JP7323723B2 (ja) | 2020-06-17 | 2023-08-08 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｎａｖ１．８阻害剤としての２－オキソイミダゾリジン－４－カルボキサミド |
| WO2022121805A1 (zh) * | 2020-12-07 | 2022-06-16 | 成都康弘药业集团股份有限公司 | 作为Nav1.8抑制剂的并环化合物及其用途 |
-
2023
- 2023-04-25 GE GEAP202516637A patent/GEAP202516637A/en unknown
- 2023-04-25 WO PCT/US2023/019879 patent/WO2023211990A1/en not_active Ceased
- 2023-04-25 CA CA3256486A patent/CA3256486A1/en active Pending
- 2023-04-25 IL IL316433A patent/IL316433A/en unknown
- 2023-04-25 PE PE2024002316A patent/PE20251183A1/es unknown
- 2023-04-25 KR KR1020247039008A patent/KR20250006217A/ko active Pending
- 2023-04-25 EP EP23725500.5A patent/EP4514789A1/en active Pending
- 2023-04-25 JP JP2024563159A patent/JP2025516005A/ja active Pending
- 2023-04-25 CR CR20240512A patent/CR20240512A/es unknown
- 2023-04-25 CN CN202380049371.6A patent/CN119585247A/zh active Pending
- 2023-04-25 AU AU2023263309A patent/AU2023263309A1/en active Pending
-
2024
- 2024-10-22 JO JOJO/P/2024/0238A patent/JOP20240238A1/ar unknown
- 2024-10-23 MX MX2024013065A patent/MX2024013065A/es unknown
- 2024-10-24 DO DO2024000215A patent/DOP2024000215A/es unknown
- 2024-10-25 CL CL2024003258A patent/CL2024003258A1/es unknown
- 2024-11-20 CO CONC2024/0015763A patent/CO2024015763A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2024003258A1 (es) | 2025-02-14 |
| CA3256486A1 (en) | 2023-11-02 |
| DOP2024000215A (es) | 2025-04-30 |
| IL316433A (en) | 2024-12-01 |
| MX2024013065A (es) | 2024-12-06 |
| EP4514789A1 (en) | 2025-03-05 |
| CN119585247A (zh) | 2025-03-07 |
| CO2024015763A2 (es) | 2025-02-13 |
| AU2023263309A1 (en) | 2024-12-05 |
| JOP20240238A1 (ar) | 2024-10-22 |
| KR20250006217A (ko) | 2025-01-10 |
| PE20251183A1 (es) | 2025-04-23 |
| CR20240512A (es) | 2025-03-03 |
| WO2023211990A1 (en) | 2023-11-02 |
| JP2025516005A (ja) | 2025-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEAP202416430A (en) | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels | |
| CR20240512A (es) | Inhibidores de amida heterocíclica bicíclica de sodio activado por voltaje 1.8 (nav1.8) para el tratamiento del dolor | |
| GEAP202616866A (en) | 2-azabicyclo[2.2.1]heptane kras inhibitors | |
| MX2024001893A (es) | Compuestos heterociclicos y metodos de uso. | |
| MX2023012726A (es) | Compuestos heterociclicos y metodos de uso. | |
| SA522432955B1 (ar) | Kras g12c مثبطات | |
| MX2024001824A (es) | Compuestos heterociclicos y metodos de uso. | |
| GEAP202416515A (en) | Quinoline compounds as inhibitors of kras | |
| MX2024011056A (es) | Compuesto heterociclico para inducir la degradacion de la proteina kras mutante g12d. | |
| MX2023007192A (es) | Inhibidores de prmt5. | |
| EA202190630A1 (ru) | Способы комбинированной терапии | |
| GEAP202115385A (en) | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors | |
| GEAP202516632A (en) | Heteroaryl compounds for the treatment of pain | |
| EA201991894A1 (ru) | ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
| GEAP202516634A (en) | Heteroaryl compounds for the treatment of pain | |
| EA201400111A1 (ru) | Ингибиторы mek и способы их применения | |
| EA202190686A1 (ru) | 5-7-членные гетероциклические амиды в качестве ингибиторов jak | |
| ATE522526T1 (de) | 4-(3-(2-(phenyl)morpholino)-2-oxopyrrolidin-1-y )-n-(thiazol-2-yl)benzolsulfonamidderivate und verwandte verbindungen als ionenkanalmodulatoren zur behandlung von schmerzen | |
| PH12021553248A1 (en) | Heterocyclic monoacylglycerol lipase (magl) inhibitors | |
| EA202192746A1 (ru) | Гетероциклические соединения и их применение | |
| MX2017014715A (es) | Benzamidas sustituidas y metodos para utilizarlas. | |
| PH12022550078A1 (en) | Enzyme inhibitors | |
| MX2025002519A (es) | Derivados de piridazinona como degradadores de kat2 para el tratamiento de trastornos proliferativos | |
| MX2024006684A (es) | Inhibidores de hdac novedosos y uso terapéutico de estos. | |
| EA201891319A1 (ru) | Соединения алкилдигидрохинолинсульфонамида |